Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade

Abstract

Immune checkpoint blockade is a promising approach to treat lung cancer, however, immune related adverse events hold back success in some patients. Here authors show that regulatory B cells fail to limit self-reactive T cells in these patients, and B cell phenotyping prior treatment may identify those at risk for these unfavourable outcomes.